Navigation Links
Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Date:6/5/2008

SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs Global Healthcare Conference in Dana Point on Wednesday, June 11, 2008 at 1:20 p.m. PT. Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation will be Web cast, and a recording will be made available following the event. The Web cast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live Web cast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
2. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
3. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
4. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
5. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
6. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
8. Amylin Pharmaceuticals to Webcast First Quarter Results
9. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
11. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar ... has secured $2M in funding from an impressive group of investors, including Rev1 ... Thrive Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering ...
(Date:8/16/2017)... WAKEFIELD, Mass. , Aug. 16, 2017  This year,s edition of ... global leader in life sciences workforce solutions, has made the list for ... Inc. 5000 recognizes the nation,s fastest-growing private companies based on a set ... Fast 50, which includes the fastest-growing companies in the Bay ... Inc. 5000 ...
(Date:8/15/2017)... Aug. 15, 2017 After spending the past two years ... crowdsourced data collection, GeneFo now offers this platform to healthcare stakeholders ... amplifying support, adherence, and data collection vis a vis their members, ... the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... that accelerate pharmaceutical and biotherapeutics development, announces the launch of the new ... needed to gain kinetic binding data for a wide range of molecules, including ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):